Hepatitis C Support Group
Hepatitis C is a blood-borne viral disease which can cause liver inflammation, fibrosis, cirrhosis and liver cancer. The hepatitis C virus (HCV) is spread by blood-to-blood contact with an infected person's blood. Many people with HCV infection have no symptoms and are unaware of the need to seek treatment. Hepatitis C infects an estimated 150-200 million people worldwide.
"Johnson & Johnson is asking for approval of the drug in combination with pegylated interferon and ribavirin."
ummmmm -- no, thanks. Who wants THIS? Have to take it with InterFEARon? Riba is bad enough (not that I've done it, but we know...), but what are they thinking? We heppers know that an all oral is going to be available for us in the near future, whatever that may be, but it's gotta happen by late 2014, I'd guess (for Gen 1's - earlier for other Gens).
believe I did it. I was so nave!! My wife was as well!! We
didn't do our homework worrying about other family members.
My final blood work is Friday. I'm done!!!
"Hepatitis C is a slow-developing disease, so there's no immediate rush to treat newly diagnosed patients as witnessed by the drop off in sales of Vertex Pharmaceuticals' (NASDAQ: VRTX ) Incivek.
In the first quarter, sales of the drug, which also has to be used in combination with pegylated interferon, fell 42% year over year. It's hard to see how simeprevir plus pegylated interferon would make inroads with doctors with all-oral hepatitis C combinations in the works."
It's obvious this author doesn't have a clue as to why sales for vertex has dropped off so much and the fact that he wrote that he thinks sakes for both new drugs will be far less than projected!!! What a PHUCKIN idiot!!!
"Likewise, it's hard to see initial blustery sales for Gilead's sofosbuvir, which will be used in combination with pegylated interferon and ribavirin in genotype 1 patients, the most common hepatitis C genotype in the U.S.
For both drugs, the approvals are just a means to the end -- the end being part of an all-oral drug cocktail. Interestingly, sofosbuvir and simeprevir worked really well together without pegylated interferon in a small clinical trial.
Once they're both approved, doctors could prescribe a combination of the two drugs off label to patients, but given the aforementioned slowly developing nature of the disease, it seems unlikely that they'd go that route without extra data.
Depending on how Gilead and Johnson & Johnson price their drugs, there could be a cost issue as well; insurers may be unwilling to reimburse for the two drugs off label."
Judging from what this jerk wrote above, I don't have any faith in one word he wrote in this article because he obviously lacks any knowledge of how the FDA works and what a Priority Review is or how long it will take for approval once it designated as such...
What a PHUCKIN ASSHOLE!!! Whoever is depending on this schmuck's advice & counsel to invest their money with should fire the jerk on the spot just from what he writes in this article.
Respectfully, (For the most part yet none to this author!)
HANK
Doesn't this schmuck know that the Dr.s can work around the mandatory Interferon?Riba requirement by prescribing such a low dose to the patient and only for a very short period of time if indeed be necessary once the patient becomes SVR???
Or to avoid it all together with the explanation that the patient needed to be on the orals first before starting them on the IFN.
It's obvious that he doesn't!!! Too many ways to get around the Ifn/Riba requirement is what my Dr. told me and he isn't alone in these workarounds!
Respectfully,
HANK
But anywho, I'm enjoying my track-side seat @ the races. Like CatM, waiting for fear free. And I do believe cirrhotics will be a priority for treatment because it will be more cost effective than treating further progression of the disease.
The future looks good for us hep c folks now..
You will do well :^)
thanks